Multiple sclerosis: Pathology, diagnosis and treatments

被引:227
作者
Huang, Wen-Juan [1 ]
Chen, Wei-Wei [1 ]
Zhang, Xia [1 ]
机构
[1] Xuzhou Cent Hosp, Dept Neurol, 199 Jiefang South Rd, Xuzhou 221009, Jiangsu, Peoples R China
关键词
multiple sclerosis; pathophysiology; treatment options; diagnostic criteria; PLACEBO-CONTROLLED PHASE-3; CLINICAL-COURSE; DOUBLE-BLIND; ORAL BG-12; T-CELLS; DISEASE; LESIONS; MS; DEMYELINATION; INFLAMMATION;
D O I
10.3892/etm.2017.4410
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Multiple sclerosis (MS) is a complex neurodegenerative disease affecting the central nervous system (CNS). The onset of MS has been typically observed in individuals aged from 20 to 40-years, with the female to male ratio of 1:2. MS appears as abrupt onset of focal sensory disturbances that is accompanied by unilateral painless damage of vision, double vision, limb weakness, unsteadiness of gait, and bowel or bladder symptoms. Whereas the exact etiology of the disease is unknown, observational research has suggested genetic and environment influences through an underlined pathophysiology widely believed to be autoimmune in nature. Indeed, plaque of demyelination inside of the CNS with relative conservation of axons remains the clinical symptoms of MS. However, considerable advances in understanding the pathology have contributed to an early diagnosis, particularly the exact neuroanatomical setting of plaques. Accordingly, magnetic resonance imaging has been considered as the primarily adjunctive modality for the constant detection of abnormal white matter. In addition, the analysis of cerebrospinal fluid contents has also been of interest for the diagnosis to discriminate other affections such infection or vasculitis. These resulted in a broad variety of therapies that considerably control the activity and change the course and prognosis of the disease. In the present review, we evaluate the current state of knowledge on MS with emphasis on the pathology itself, the diagnosis and common therapeutical approaches accurately used.
引用
收藏
页码:3163 / 3166
页数:4
相关论文
共 47 条
[1]   Environmental risk factors for multiple sclerosis. Part I: The role of infection [J].
Ascherio, Alberto ;
Munger, Kassandra L. .
ANNALS OF NEUROLOGY, 2007, 61 (04) :288-299
[2]   Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].
Bielekova, B ;
Catalfamo, M ;
Reichert-Scrivner, S ;
Packer, A ;
Cerna, M ;
Waldmann, TA ;
McFarland, H ;
Henkart, PA ;
Martin, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946
[3]   Acute axonal injury in multiple sclerosis -: Correlation with demyelination and inflammation [J].
Bitsch, A ;
Schuchardt, J ;
Bunkowski, S ;
Kuhlmann, T ;
Brück, W .
BRAIN, 2000, 123 :1174-1183
[4]   Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease [J].
Bjartmar, C ;
Wujek, JR ;
Trapp, BD .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) :165-171
[5]   Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study [J].
Calabresi, Peter A. ;
Kieseier, Bernd C. ;
Arnold, Douglas L. ;
Balcer, Laura J. ;
Boyko, Alexey ;
Pelletier, Jean ;
Liu, Shifang ;
Zhu, Ying ;
Seddighzadeh, All ;
Hung, Serena ;
Deykin, Aaron .
LANCET NEUROLOGY, 2014, 13 (07) :657-665
[6]   Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades [J].
Celius, E. G. ;
Smestad, C. .
ACTA NEUROLOGICA SCANDINAVICA, 2009, 120 :27-29
[7]   Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation [J].
Charo, IF ;
Ransohoff, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :610-621
[8]   Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial [J].
Chataway, Jeremy ;
Schuerer, Nadine ;
Alsanousi, Ali ;
Chan, Dennis ;
MacManus, David ;
Hunter, Kelvin ;
Anderson, Val ;
Bangham, Charles R. M. ;
Clegg, Shona ;
Nielsen, Casper ;
Fox, Nick C. ;
Wilkie, David ;
Nicholas, Jennifer M. ;
Calder, Virginia L. ;
Greenwood, John ;
Frost, Chris ;
Nicholas, Richard .
LANCET, 2014, 383 (9936) :2213-2221
[9]   The window of therapeutic opportunity in multiple sclerosis [J].
Coles, AJ ;
Cox, A ;
Le Page, E ;
Jones, J ;
Trip, SA ;
Deans, J ;
Seaman, S ;
Miller, DH ;
Hale, G ;
Waldmann, H ;
Compston, DA .
JOURNAL OF NEUROLOGY, 2006, 253 (01) :98-108
[10]   Multiple sclerosis [J].
Compston, Alastair ;
Coles, Alasdair .
LANCET, 2008, 372 (9648) :1502-1517